No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 698-703

  Williams, K J ^a   Heighway, J ^a   Birch, J M ^a   Norton, J D ^a   Scott, D ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Dominant negative effect; G1 arrest; Li Fraumeni; p53

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; FAMILIAL CANCER; HUMAN; HUMAN CELL; IRRADIATION; LYMPHOBLASTOID CELL LINE; MISSENSE MUTATION; PRIORITY JOURNAL; RADIATION RESPONSE; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; BURKITT LYMPHOMA; CELL CULTURE; DNA DAMAGE; FEMALE; FLOW CYTOMETRY; GAMMA RADIATION; GENETICS; IMMUNOBLOTTING; LYMPHOCYTE; MALE; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; RADIOGRAPHY;

PROTEIN P53;

BURKITT LYMPHOMA; DNA DAMAGE; FEMALE; FLOW CYTOMETRY; G1 PHASE; GAMMA RAYS; HUMANS; IMMUNOBLOTTING; LI-FRAUMENI SYNDROME; LYMPHOCYTES; MALE; S PHASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029665611     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.424     Document Type: Article

References (26)

1. BECH-HANSEN NT, BLATTNER WA, SELL BM, MCKEE EA, LAMPKIN BS, FRAUMENI JF AND PATERSON MC (1981). Transmission of in vitro radioresistance in a cancer-prone family. Lancet, 1, 1335-1337.
2. BIRCH JM, HARTLEY AL, SANTIBÁÑEZ-KOREF MF, TRICKER KH, PROSSER J, CONDIE A, KELSEY AM, HARRIS M, MORRIS JONES PH, BINCHY A, CROWTHER D, CRAFT AW, EDEN OB, EVANS DGR, THOMPSON E, MANN JR AND MARTIN J. (1994). Prevalance and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res., 54, 1298-1304.
3. BISCHOFF FZ, YIM SO, PATHAK S, GRANT G, SICILIANO MJ, GIOVANELLA BC, STRONG LC AND TAINSKY MA. (1990). Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: Aneuploidy and spontaneous immortalization. Cancer Res., 50, 7979-7984.
4. CAMPLEJOHN RS, PERRY P, HODGSON SV, TURNER G, WILLIAMS A, UPTON C, MACGEOCH C, MOHAMMED S AND BARNES DM. (1995). A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Br. J. Cancer, 72, 654-662.
5. EL-DEIRY, TOKINO T, VELCULESCU VE, LEVY DB, PARSONS R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumour suppression. Cell, 75, 817-825.
6. HARLOW E AND LANE DP. (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory. Press: Cold Spring Harbor, NY.
7. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTEIN B AND CRAIG RW. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
8. KASTAN MB, ZHAN Q, EL-DEIRY WS, CARRIER F, JACKS T, WALSH WV, PLUNKETT BS, VOGELSTEIN B AND FORNACE AJ. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell, 71, 587-597.
9. KUERBITZ SJ, PLUNKETT BS, WALSH WV AND KASTAN MB. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci., 89, 7491-7495.
10. LALLE P, MOYRET-LALLE C, WANG Q, VIALLE JM, NAVARRO C, BRESSAC-DE PAILLERETS B, MAGAUD JP AND OZTURK M. (1995). Genomic stability and wild-type p53 function of lymphoblastoid with germline p53 mutation. Oncogene 10, 2447-2454.
11. LANE DP. (1992). p53, guardian of the genome. Nature, 358, 15-16.
12. LI FP AND FRAUMENI JF. (1969). Rhabdomyosarcoma in children: Epidemiologic study and identification of a familial cancer syndrome. J. Natl Cancer Inst., 43, 1365-1373.
13. LIVINGSTONE LR, WHITE A, SPROUSE J, LIVANOS E, JACKS T AND TISTY TD. (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935.
14. MAGRATH IT, PIZZO PA, WHANG-PENG J, DOUGLASS EC, ALABASER O, GERBER P, FREEMAN CB AND NOVIKOVS L. (1980). Characterisation of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. J. Natl Cancer Inst., 64, 465-476.
15. MALKIN D, LI FP, STRONG LC, FRAUMENI JF, NELSON CE, KIM DH, KASSEL J, GRYKA MA, BISCHOFF FZ, TAINSKY MA AND FRIEND SH. (1990). Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233-1238.
16. MILLER CW, CHUMAKOV A, SAID J, CHEN DL, ASLO A AND KOEFFLER HP. (1993). Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene, 8, 1815-1824.
17. MILNER J AND MEDCALF EA. (1991). Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell, 65, 765-774.
18. O'CONNOR PM, JACKMAN J, JONDLE D, BHATIA K, MAGRATH IT AND KOHN KW. (1993). Role of p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53, 4776-4780.
19. 2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndrome. Radiat. Res., 136, 236-240.
20. PRIVES C. (1994). How loops, B sheets and a helices help us to understand p53. Cell, 78, 543-546.
21. SANTIBÁÑEZ-KOREF MF, BIRCH JM, HARTLEY AL, MORRIS JONES PH, CRAFT AW, EDEN T, CROWTHER D, KELSEY AM AND HARRIS M. (1991). p53 germline mutations in Li-Fraumeni syndrome. Lancet, 338, 1490-1491.
22. SPROSTON ARM, BOYLE JM, HEIGHWAY J AND SCOTT D. (1996). Fibroblasts from Li-Fraumeni patients are resistant to low dose-rate irradiation. Int. J, Radiat. Biol. (in press).
23. SRIVASTAVA S, ZOU Z, PIROLLO K, BLATTNER W AND CHANG EH. (1990). Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature, 348, 747-749.
24. SRIVASTAVA S, WANG S, TONG YA, PIROLLO K AND CHANG EH. (1993). Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene, 8, 2449-2456.
25. WAGA S, HANNON GJ, BEACH D AND STILLMAN B. (1994). The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature, 369, 574-578.
26. XIONG Y, HANNON GJ, ZHANG H, CASSO D, KOBAYASHI R AND BEACH D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.